ABSTRACT
INTRODUCTION
Patients with ER/PR/HER2-negative breast cancer subtype have been difficult to treat due to tumor heterogeneity and lack of definitive targets for targeted therapeutics (1) . Chemotherapy remains the standard of care for patients as hormonal therapies and HER2-targeting agents are not indicated (2) . Paclitaxel is a microtubule stabilizing agent widely used in breast cancer (3) .
Although ER/PR/HER2-negative breast cancer responds to these and other conventional agents, patients become resistant to treatment and relapse more frequently than patients with other breast cancer subtypes (4) . c-Src is an oncogenic non-receptor tyrosine kinase that is up-regulated in approximately half of all breast cancers (5) . Src kinase has been associated with breast cancer proliferation, angiogenesis, cell motility, migration/invasion and metastasis (6, 7) . The role of Src in proliferation, migration and invasion, coupled with the elevated Src expression in breast cancer make Src a promising target for development of therapeutics. Moreover, Src inhibition has been identified as a therapeutic target for ER/PR/HER2-negative breast cancer (8) . However as a single agent, the broad specificity Src/tyrosine kinase inhibitor dasatinib (Sprycel) resulted in only a modest response rate of 5% in a phase II trial of 43 patients with advanced ER/PR/HER2-negative breast cancer (4, 9) . Another Src inhibitor, Sarcatinib failed as monotherapy in hormone receptor negative breast cancer patients (10) . It is unknown why these compounds failed in these early trials or whether combinations with other drugs may have resulted in better response.
Peptidomimetics represent a novel class of drugs that interact with the peptide substrate sites of proteins. KX-01 (clinical-reference, KX2-391) was developed as a 'first in class' peptidomimetic Src kinase inhibitor that binds to the peptide substrate site and inhibits Src kinase activity and downstream targets (11, 12) . Orally bioavailable KX-01 completed phase 1 clinical testing (13) and is currently in phase 2 trials for prostate cancer (14) as well as phase 1b trial for Acute Myeloid Leukemia (15) . In addition to Src inhibition, KX-01 has a second mechanism of action (MOA) through binding to novel sites on alpha-beta tubulin heterodimer that results in inhibition of microtubule polymerization (16) . The dual activity of KX-01 to both inhibit Src and to disrupt microtubules may provide KX-01 with additional antitumor activity for ER/PR/HER2-negative breast cancer in comparison to compounds that exhibit Src inhibition alone.
A previous study from this laboratory demonstrated that KX-01 combined with tamoxifen resulted in synergistic growth inhibition in ER positive xenograft tumors, in part, through reduced phosphorylation and transcriptional activity of ERα (11) . Given the elevated expression of Src in ER/PR/HER2-negative breast cancer (17) , the present study evaluated the preclinical activity of peptidomimetic Src inhibitor KX-01 alone, and in combination with chemotherapeutic drug paclitaxel. Since Src has been implicated in invasion and metastasis, this study also examined the anti-invasive and anti-metastatic potential of KX-01 both in vitro and in vivo.
MATERIALS AND METHODS

Cell lines, culture conditions and reagents
The human breast cancer cell lines MDA-MB-231, MDA-MB-157, and MDA-MB-468 were obtained from the American Type Culture Collection. These cell lines lack expression of ERα, and PR and do not exhibit amplification/overexpression of HER2 (18) . The cells were cultured in DMEM medium (Invitrogen, Gibco) supplemented with 10% FBS, 1% penicillin/streptomycin 5 in a humidified incubator at 37°C containing 5% CO 2 
MTT and Apoptosis assay
MTT and apoptosis assays (ELISA, Roche) were performed as described (11) . Cell growth was measured in MDA-MB-231, MDA-MB-157, MDA-MB-468 cells after incubation with vehicle and varying concentrations of KX-01, paclitaxel, doxorubicin or dasatinib (5, 10, 25, 50, 100, 250nmol/L) for 48h. Cell growth was expressed as percent of vehicle. Apoptosis was evaluated 24h after drug incubation.
Invasion assay
Invasion assays were performed as described (19) . Cells were incubated with KX-01 (10, 25, 50nmol/L) for 24h. Invaded cells were counted (Image J software) and photomicrographed.
The correction for growth inhibition by KX-01 is described in 'Supplementary Methods'. The number of cells invaded was counted and percent invasion was calculated by setting vehicle as 100%. The invasion was normalized to cell number as shown below, percent invaded cells/percent viable cells × 100 = relative invasion (%).
3D-on top assay
This assay was performed as described (20) and is described in 'Supplementary Methods'. KX-01 was added to the medium (10, 25, 50nmol/L) at the time of cell plating. The Matrigel-medium mixture and KX-01 was replaced every 2days for the duration of the 4days and photomicrographed.
Scratch assay
Scratch assay was performed as described (19) . Cells were incubated with vehicle or KX-01 (5, 10 and 25nmol/L) for 24h after scratch and wound closure was photographed at 40X magnification. Wound closure was evaluated by measuring wound width by Image J. Percent gap closure was calculated as: % gap closure = Gap area at time 0 -Gap area at time 24h x 100% Gap area at time 0
Animals
Female athymic NUDE mice (BALB/c) aged between 4-5 weeks obtained from Charles River (Indianapolis, IN) were housed in sterile cages and maintained in pathogen-free aseptic rooms with 12h/12h light/dark schedule. Mice were fed with autoclaved food pellets and water ad libitum. All experiments were performed in accordance with approved IACUC protocol #2941R2 from Tulane University.
Tumor xenograft studies
Xenograft procedures and KX-01 oral dosing were as described (11) . Briefly, mammary fat pad tumors were established by injecting 5x10 
Quantification of micrometastases
Human DNA within the mouse organs was measured using quantitative real time RT-PCR to detect human chromosome-17. The detection is based on a human-specific α-satellite DNA sequence of the centromere region of human chromosome 17 (21) . After necropsy (n=5, animals/group), mouse organs were removed, homogenized, and DNA extracted and quantified using a NanoDrop Spectrophotometer (ThermoScientific). Quantitative real-time PCR procedure is described in 'Supplementary Methods'. The CT value obtained for human chromosome -17 was normalized to housekeeping gene GAPDH (CT value) that detected both mouse and human GAPDH as a measure of total DNA for the samples (GAPDH served as a loading control). Since the extracted DNA could have both mouse and human DNA, we used primers that detected both mouse and human GAPDH. ΔCT=CT value of human chromosome-17 gene minus CT value of mouse/human GAPDH. Standard curves (SC) for number of human cells within a mouse organ were generated by serial additions of MCF-7 human breast cancer cells [10 6 , 10 was used as an internal control. Real time RT-PCR for human/mouse GAPDH was performed as described (22) . Real-time PCR-assays were performed in triplicate. The SC for lung, liver and femur was used to calculate the absolute number of human cells present in the lung, liver and bone. Non-linear regression analysis was used to interpolate unknowns from the SC (GraphPad Prism5). The detection limit for real-time PCR in this assay was 100 human cells per mouse lung, liver or femur.
Statistical Analysis
Data were expressed as mean ± SD. P<0.05 was considered significant. The mean and S.D. were calculated using Microsoft Excel or GraphPad Prism 5 software (La Jolla, CA).
Statistical significance was determined by two-sample student t-tests (P<0.05) (two-tailed) and one-way ANOVA followed by Newman-Keuls multiple comparison test. Combination indices (CI) for combination drug treatments were performed using Calcusyn software (Biosoft, Cambridge, UK). The extent of cooperation between KX-01 with paclitaxel was determined from the CI as follows: CI<1.0 indicated synergism; CI = 1.0 indicated additivity; CI>1.0 indicated antagonism (23) .
RESULTS
Chemical structures of KX-01, Dasatinib and Paclitaxel were shown in Fig.1A .
Effect of KX-01 and dasatinib on ERα negative breast cancer cells
The ATP-analogue Src-inhibitor dasatinib was demonstrated to inhibit growth of MDA-MB-231 breast cancer cells, but not ERα/PR/HER2-negative MDA-MB-468 cells (18) (Fig.1B) . Moreover KX-01 induced significant apoptosis in MDA-MB-468 cells at 25nmol/L, whereas dasatinib did not induce apoptosis at a 10X higher concentration (250nmol/L) (Suppl. Fig.1 ). 
Combination of KX-
Combination of KX-01 with paclitaxel induced apoptosis in MDA-MB-231 breast cancer cells
To determine whether synergistic growth inhibition by combination of paclitaxel+KX-01 resulted from increased apoptosis, an ELISA-based DNA fragmentation assay was used. KX-01 or paclitaxel at the concentrations used in Figure 1D resulted in modest apoptosis in MDA-MB-231 cells (Fig.1E) . Combination of KX-01 with paclitaxel enhanced apoptosis two-fold compared to single drug treatments (Fig.1E) .
Oral administration of KX-01 reduced growth of ER/PR/HER2-negative breast tumor xenografts in mice
MDA-MB-231 and MDA-MB-157 xenograft tumors (80-100 mm 3 ) in NUDE mice were established to determine the effect of KX-01 on tumor growth in vivo. Mice were treated with vehicle (ultra-pure water), KX-01 at 1mg/kg and KX-01 at 5mg/kg for 28 days, BID. KX-01 resulted in marked tumor growth inhibition in both tumor models ( Fig.2A and Suppl. Fig.2A ).
Mice receiving KX-01 at 1mg/kg and 5mg/kg showed reduced MDA-MB-231 tumor volume compared to vehicle from days 18 and 15, respectively (P<0.05; Fig.2A ). KX-01 at 1mg/kg and 5mg/kg reduced MDA-MB-231 tumor volume 35.3% and 79.0%, respectively ( Fig.2A) , and reduced MDA-MB-157 tumor volume 23.5% and 42.0%, respectively (Suppl. Fig.2A ). (Fig.2E,H) . To evaluate the effect of KX-01 on angiogenesis, microvessel density (MVD) was assessed by counting CD31 positive microvessels. KX-01 significantly reduced MVD (P<0.05) compared to vehicle (Fig.2F,I ). In summary, these data demonstrate that KX-01 significantly reduced growth of MDA-MB-231 tumors that was attributed, in part, to reduced tumor cell proliferation, increased apoptosis and decreased blood vessel density (modestly) that was coincident with reduced Src kinase activity in the tumors.
KX-01 decreased activity of
Combination of KX-01 with paclitaxel resulted in regression of ER/PR/HER2-negative tumor xenografts
The in vitro observations of synergistic growth inhibition of breast cancer cell lines co- 
paclitaxel reduced tumor volume by 93.0% (Fig.3A) . Most significantly, combination of KX-01 with paclitaxel resulted in complete regression of tumors in two of five mice. In MDA-MB-157 xenografts, the same single agent doses of KX-01 and paclitaxel reduced tumor volumes by 42.0% and 16.3%, respectively (Fig.3B) . Combination of KX-01+paclitaxel reduced MDA-MB-157 tumor volumes by 71.1% compared to vehicle (P<0.001; Fig.3B ). No noticeable toxicity or significant body weights reduction was observed in either drug alone or combinational treatment groups (Suppl. Fig.3A ). Hematoxylin and eosin (H&E) staining of MDA-MB-231 tumor sections revealed more acellular, necrotic regions in tumors from the combination treatment groups compared to single drug treatments (Suppl. Fig.3B, arrows) . 35 .4% (P<0.001; Fig.4A ) with no significant reduction in mouse body weight (Suppl. Fig.3C ).
Combination of KX-
Combination of KX-01 (15mg/kg) with paclitaxel (20mg/kg) resulted in 90.6% tumor regression to a volume that was markedly below the starting tumor volume (P<0.001, Fig.4A ) with approximately 10% mouse body weight reduction but without noticeable toxicity (initial mean body weight= 19.4g; final mean body weight= 17.6g; Suppl. Fig.3C ). By day 12, mice receiving KX-01+paclitaxel showed significant tumor regression compared to single treatments (P<0.001, network, as well as evidence of fragmented microtubules (arrows). Taken together, these data provide direct evidence that KX01 alone, and in combination with paclitaxel resulted in disruption of the microtubule network in tumors.
KX-01 inhibited breast cancer cell outgrowth, invasion and migration in vitro
Cell invasiveness was assessed using a 3D invasion assay in which MDA-MB-231 cells were cultured in reconstituted extracellular matrix to mimic an in vivo microenvironment (20) . 
Effect of KX-01 on MDA-MB-231 micrometastasis in vivo
Although the relatively short treatment time (40 days) for the MDA-MB-231 xenograft tumors was not sufficient for tumors to exhibit visual macrometastases to mouse organs, 40 days was sufficient to measure micrometastasis by quantitating human DNA in mouse tissues. At the termination of experiments described in Figure 3A , lung, liver, and the bone marrow from femurs were removed (n=5 mice), and the amount of human DNA in these mouse tissues was treated with KX-01 alone or paclitaxel+KX-01, the differences between these treatment groups and vehicle were not statistically significant (Fig.6B) . Additionally, there was no statistical difference between vehicle and paclitaxel alone for metastatic cells in the bone marrow (Fig.6B ).
The incidence of micrometastasis to liver in the vehicle group was 4/5 mice (80%) and the mean number of MDA-MB-231 cells in the liver for the vehicle group was 3.0x10 ER/PR/HER2-negative breast cancers are intrinsically more chemo-resistant than other breast cancer subtypes (27) . Given the lack of targeted agents and the rapid onset of chemoresistance in metastatic ER/PR/HER2-negative breast cancers, there is urgent need for novel therapeutic approaches to target these tumors. Combination of targeted agents with conventional chemotherapeutic agents are currently being investigated and have proven clinically successful in several cancers, including breast cancer (28, 29) . The present study presents KX-01 as a first in class clinical Src/pretubulin inhibitor that results in significant tumor regression when combined with standard of care chemotherapy agent paclitaxel demonstrating that this combination could be considered in the clinical setting. 
KX-01 efficacy in preclinical tumor models was correlated with strong inhibition of Src and FAK activity suggesting that Src inhibition contributed to the antitumor effect. In addition to Src inhibition, KX-01 also inhibits microtubule polymerization as a second MOA (16, 26) .
This second MOA likely contributes to the robust apoptosis and antitumor activity in comparison to drugs that exhibit only Src inhibition. In this regard, KX-01 as a single compound may exert similar effects as combination of clinical Src inhibitors with microtubule targeting chemotherapy (30) , and may also be effective in Src inhibitor-resistant tumors.
Paclitaxel stabilizes microtubules resulting in mitotic blockade and subsequent cell cycle arrest or apoptosis. Interestingly, KX-01 and paclitaxel disrupt microtubules by different means; inhibition of microtubule assembly and stabilization of microtubules, respectively, as was observed by the markedly different microtubule staining patterns in tumors exposed to these two agents (Fig.4B) . The combination of KX-01 with paclitaxel resulted in a reduced microtubule network along with fragmentation of many of the remaining microtubules. It was recently shown that microtubule inhibiting drugs can cause microtubule minus-end detachment from the microtubule organizing centers (MTOC) (31) . It is possible that KX-01 through inhibition of tubulin polymerization has a similar effect in causing microtubule detachment from MTOC.
However in the KX-01+paclitaxel group, the resulting detached microtubules are protected by paclitaxel from further KX-01-induced depolymerization thus giving rise to fragmented microtubules. It is likely that these two different mechanisms for microtubule disruption contribute to the anti-tumor synergy observed when KX-01 and paclitaxel were combined.
Invading cells produce various membrane protrusions that promote migration and proteolysis of extracellular matrix (ECM) (32) . Src has been shown to regulate microtentacles and invadopodia (32) . Src is both necessary and sufficient for the formation of invadopodia at 
sites of integrin-mediated ECM adhesion (33) . Cells coordinate focal adhesions and invadopodia to provide traction (34) . MDA-MB-231 cells are highly invasive and migratory and are shown to produce microtentacle protrusions and invadopodia (32) . Src inhibition by KX-01 significantly reduced formation of invasive stellate structures in MDA-MB-231 cells, and inhibited cell migration and invasion. These findings correlated with KX-01 inhibition of Src and focal adhesion kinase in tumors.
Metastasis is the final step in the progression of many solid tumors with the lungs, liver, and bone as frequent sites for breast cancer metastasis (35, 36) . The brief treatment period (40 days) of MDA-MB-231 xenografts permitted an evaluation of micrometastasis to mouse organs from the primary tumor. KX-01 alone or in combination with paclitaxel resulted in complete absence of detectable micrometastasis to the lung and liver. It should be noted that the reduction in micrometastasis could be attributed, in part, to the reduced primary tumor burden in the treated animals. Because the tumor xenografts had to be terminated within 30-40 days due to the large size of the primary tumors, micrometastases to mouse organs were limited and sectioning/H&E staining of mouse organs to quantitate micrometastases was not possible. As an alternate approach to measure very early micrometastases, we quantitated levels of human chromosome 17 microsatellite regions by PCR using an established procedure (21, 37) that we have previously employed (38) . Although precaution was taken to rinse mouse organs thoroughly with PBS to remove blood and blood clots prior to DNA isolation, a caveat to this procedure is the presence of any circulating tumor cells in the vasculature of the organs that could contribute to the DNA quantitation. Future studies will evaluate KX-01 in impacting multiple steps of the metastatic process using appropriate metastatic models and histopathologic methods to quantitate metastatic burden. 
